At the European Cancer Congress (ECC) 2015, Neal Shore, MD, FACS, of Carolina Urologic Research Center, Myrtle Beach, SC, discusses the first interim analysis of a phase 2, randomised, open-label, parallel group clinical trial of TAK-385, an oral gonadotropin-releasing hormone (GnRH) antagonist, for the treatment of patients with advanced prostate cancer.
Phase 2 trial of TAK-385, an oral GnRH antagonist, in prostate cancer
15th October 2015
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?